Skip to content
drillr.ai

KYMR

Kymera Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$111.06-4.07%

Price as of Jul 20, 2026

KYMR news

Kymera Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

    NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term KYMR stockholder please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. Th

    Globe Newswire ·

  2. SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR Newswire NEW YORK, July 16, 2026 NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions. If

    PR Newswire ·

  3. Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

    Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=BwITC4CwCHVYWufMF_QVzEFbf15GOZ9ZipYwdDxSgihyqIEAqr9GFA8QO1Ug0XPJbh5wxnSOqepaFyjY53IPyBK72aKnwFd8X63naB0DdLo=) (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Fe

    Globe Newswire ·

  4. Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

    Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=MuvnYV5H9dhoyjfUA-EszXajg1JVsQ8mw7IlroZqPlDV5rXp9p0fcux93sx9ESsNxHwDVuNbe38bIzB7MhUVL478LwjtjE0hMbe3Yz2IFvA=) (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral

    Globe Newswire ·

  5. Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

    Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent * Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development * With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ: BIIB), and

    Business Wire ·